Popular Articles

Cyberonics Provides Update On Depression Post-Approval Study
Cyberonics, Inc. (Nasdaq: CYBX) announced that the U.S. Food and Drug Administration ("FDA") has approved the company"s proposal to amend the protocol of its D-21 post-approval dosing study in depression patients treated with VNS Therapy(TM).
new payday loan lenders
Academy Makes Recommendations To Build Clinical Academic Capacity
UK clinical research is currently benefiting from significant additional investment from Government and other research funders. A challenge for funders and institutions is to allocate res across the range of clinical academic specialties, to most effectively pursue research and its translation into improved healthcare.
News of the day
The Dawn Of A New Era In Cancer Treatment
A new article in Scrip World Pharmaceutical News highlights enormous change in cancer medicine with highly personalised treatments, patient top-up payments in some markets, response-related payments and even refunds when there is no response to a treatment, all driving the future of cancer care worldwide.
Cardiovascular

"Artificial Golgi" May Provide New Insight Into Key Cell Structure

Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle. That key structure inside cells helps process and package hormones, enzymes, and other substances that allow the body to function normally. The lab-on-a-chip device could lead to a faster and safer method for producing heparin, the widely used anticoagulant or blood thinner, the researchers note. Their study is scheduled for the Aug. 12 issue of the Journal of the American Chemical Society, a weekly publication. The Golgi organelle is named for Camillo Golgi, the Italian scientist and Nobel Prize winner who discovered the structure in 1898. It is composed of a network of sacs, stacked like a deck of playing cards, located inside cells. In the new study, Robert Linhardt and colleagues point out that Golgi bodies are one of the most poorly understood organelles (specialized structures inside cells) in the human body. Scientists already know, however, that the organelles play a key role in producing heparin, a substance that helps prevent clotting. The researchers describe development of a prototype lab-on-a-chip device that closely mimics the natural Golgi apparatus. They showed in lab tests that the device could quickly and efficiently produce heparin. It did so in an assembly-line fashion using a combination of enzymes, sugars and other raw materials and demonstrated that the substance has a strong clot-fighting potential. In the future, an "artificial Golgi" could lead to a faster and safer method for producing heparin, the scientists suggest. Journal of the American Chemical Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):